Inhaled corticosteroids in ventilated preterm neonates: a non-randomized dose-ranging study

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Pharmacology

Background:

• Inhaled corticosteroids (ICS) offer targeted treatment for bronchopulmonary dysplasia (BPD) with fewer systemic effects than oral steroids.
• Optimal dosing of ICS for high-risk infants developing BPD remains undefined.
• This study aimed to establish an effective ICS dose for ventilator-dependent infants to aid extubation or decrease oxygen requirements.

Purpose of the Study:

• To determine an effective dose of inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) for ventilator-dependent infants.
• To assess the efficacy of HFA-BDP in facilitating extubation or reducing fractional inspired oxygen concentration (FiO2).
• To evaluate oxygen requirements, complications, and long-term neurodevelopmental outcomes.

Main Methods:

• A non-randomized dose-ranging trial involving 41 ventilator-dependent infants (born <32 weeks GA or <1250 g).
• Infants received aerosolized HFA-BDP at doses of 200, 400, 600, or 800 μg twice daily for one week.
• Primary outcome was therapeutic efficacy (≥60% success in extubation or FiO2 reduction >75%).

Main Results:

• Therapeutic efficacy was not achieved in any dosing group.
• A significant reduction in post-treatment FiO2 was observed at the 800 μg twice daily dose.
• No clear trends in long-term neurodevelopmental outcomes were identified.

Conclusions:

• Current ICS doses studied did not demonstrate therapeutic efficacy for ventilator-dependent preterm infants.
• The 800 μg twice daily dose of HFA-BDP significantly reduced oxygen requirements.
• Larger randomized trials are necessary to confirm ICS efficacy in managing infants at high risk for BPD.